NAFL
MCID: NNL005
MIFTS: 62

Non-Alcoholic Fatty Liver Disease (NAFL)

Categories: Cancer diseases, Cardiovascular diseases, Genetic diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Non-Alcoholic Fatty Liver Disease

MalaCards integrated aliases for Non-Alcoholic Fatty Liver Disease:

Name: Non-Alcoholic Fatty Liver Disease 12 25 17
Nonalcoholic Fatty Liver Disease 25 37 15
Non-Alcoholic Fatty Liver 12 17
Fatty Liver 25 55
Steatosis 25 17
Nafld 12 25
Susceptibility to Nonalcoholic Fatty Liver Disease 6
Non-Alcoholic Steatohepatitis 25
Nonalcoholic Steatohepatitis 25
Nafl 12
Nash 25

Classifications:



External Ids:

Disease Ontology 12 DOID:0080208 DOID:0080546
KEGG 37 H01333

Summaries for Non-Alcoholic Fatty Liver Disease

Genetics Home Reference : 25 Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat. The fat deposits in the liver associated with NAFLD usually cause no symptoms, although they may cause increased levels of liver enzymes that are detected in routine blood tests. Some affected individuals have abdominal pain or fatigue. During a physical examination, the liver may be found to be slightly enlarged. Between 7 and 30 percent of people with NAFLD develop inflammation of the liver (non-alcoholic steatohepatitis, also known as NASH), leading to liver damage. Minor damage to the liver can be repaired by the body. However, severe or long-term damage can lead to the replacement of normal liver tissue with scar tissue (fibrosis), resulting in irreversible liver disease (cirrhosis) that causes the liver to stop working properly. Signs and symptoms of cirrhosis, which get worse as fibrosis affects more of the liver, include fatigue, weakness, loss of appetite, weight loss, nausea, swelling (edema), and yellowing of the skin and whites of the eyes (jaundice). Scarring in the vein that carries blood into the liver from the other digestive organs (the portal vein) can lead to increased pressure in that blood vessel (portal hypertension), resulting in swollen blood vessels (varices) within the digestive system. Rupture of these varices can cause life-threatening bleeding. NAFLD and NASH are thought to account for many cases of cirrhosis that have no obvious underlying cause (cryptogenic cirrhosis); at least one-third of people with NASH eventually develop cirrhosis. People with NAFLD, NASH, and cirrhosis are also at increased risk of developing liver cancer (hepatocellular cancer). NAFLD is most common in middle-aged or older people, although younger people, including children, are also affected. It is often considered as part of a group of conditions known collectively as the metabolic syndrome; in addition to NAFLD, the metabolic syndrome includes obesity, type 2 diabetes or pre-diabetes (insulin resistance), high levels of fats (lipids) such as cholesterol and triglycerides in the blood, and high blood pressure (hypertension). However, a person with NAFLD may not have all or any of the other conditions that make up the metabolic syndrome, and individuals with some or all of those conditions may not have NAFLD.

MalaCards based summary : Non-Alcoholic Fatty Liver Disease, also known as nonalcoholic fatty liver disease, is related to psoriasis and hepatocellular carcinoma. An important gene associated with Non-Alcoholic Fatty Liver Disease is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Non-alcoholic fatty liver disease (NAFLD) and Glycerolipid metabolism. The drugs Losartan and Milk thistle have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and heart.

Disease Ontology : 12 A fatty liver disease characterized by the storing of excess fat in liver cells which is not caused by heavy alcohol use.

KEGG : 37
It has been reported that those patients with nonalcoholic fatty liver disease (NAFLD) are probably more common in those individuals with metabolic syndrome, which includes obesity and type 2 diabetes mellitus. The spectrum of NAFLD ranges from simple steatosis to steatohepatitis with hepatic inflammation and fibrosis, known as nonalcoholic steatohepatitis (NASH). Of those with NASH, approximately 20% will go on to develop cirrhosis and hepatocellular carcinoma.

Wikipedia : 75 Non-alcoholic fatty liver disease (NAFLD) is excessive fat build-up in the liver due to causes other... more...

Related Diseases for Non-Alcoholic Fatty Liver Disease

Diseases related to Non-Alcoholic Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 826)
# Related Disease Score Top Affiliating Genes
1 psoriasis 31.7 MIR21 MIR200A MIR122
2 hepatocellular carcinoma 30.9 MIR34A MIR26A1 MIR21 MIR200B MIR200A MIR151A
3 lymphoma, hodgkin, classic 30.5 MIR21 MIR200A MIR140
4 colorectal cancer 30.2 MIR34A MIR26A1 MIR21 MIR140 MIR132 MIR126
5 muscular dystrophy, duchenne type 30.2 MIR34A MIR29C MIR21 MIR154 MIR130A
6 breast cancer 29.8 MSR1 MIR34A MIR29C MIR21 MIR200B MIR200A
7 ovarian cancer 29.7 MIR29C MIR21 MIR200B MIR200A MIR140 MIR126
8 prostate cancer 29.6 MSR1 MIR34A MIR21 MIR200B MIR151A MIR126
9 glioblastoma 29.5 MIR34A MIR21 MIR130A MIR10B
10 lung cancer 29.1 MIR34A MIR33A MIR29C MIR26A1 MIR21 MIR200B
11 fatty liver disease, nonalcoholic 2 12.6
12 fatty liver disease, nonalcoholic 1 12.5
13 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 12.4
14 lipoatrophy with diabetes, leukomelanodermic papules, liver steatosis, and hypertrophic cardiomyopathy 12.2
15 non-alcoholic steatohepatitis 12.2
16 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 12.2
17 hypertriglyceridemia, transient infantile 12.1
18 lipodystrophy, familial partial, type 2 12.0
19 liver disease 11.8
20 fatty liver disease 11.8
21 reye syndrome 11.7
22 congenital generalized lipodystrophy 11.4
23 familial partial lipodystrophy 11.4
24 mitochondrial dna depletion syndrome 4a 11.4
25 adrenomyodystrophy 11.4
26 visceral steatosis, congenital 11.4
27 corticosteroid-binding globulin deficiency 11.2
28 lipodystrophy, congenital generalized, type 2 11.2
29 3-methylglutaconic aciduria, type v 11.2
30 lipodystrophy, congenital generalized, type 3 11.2
31 interstitial lung and liver disease 11.2
32 lipodystrophy, familial partial, type 6 11.2
33 fibrosis, neurodegeneration, and cerebral angiomatosis 11.2
34 lipid metabolism disorder 11.2
35 hyperlipidemia, familial combined, 2 11.1
36 neutral lipid storage disease with myopathy 11.1
37 aromatase deficiency 11.1
38 combined oxidative phosphorylation deficiency 16 11.1
39 morbid obesity and spermatogenic failure 11.1
40 chylomicron retention disease 11.1
41 pearson marrow-pancreas syndrome 11.1
42 lipodystrophy, congenital generalized, type 1 11.1
43 hypermanganesemia with dystonia 1 11.1
44 lipodystrophy, congenital generalized, type 4 11.1
45 lipodystrophy, familial partial, type 5 11.1
46 combined oxidative phosphorylation deficiency 21 11.1
47 infantile liver failure syndrome 2 11.1
48 mitochondrial dna depletion syndrome 15 11.1
49 bile acid synthesis defect, congenital, 6 11.1
50 liver cirrhosis 11.0

Graphical network of the top 20 diseases related to Non-Alcoholic Fatty Liver Disease:



Diseases related to Non-Alcoholic Fatty Liver Disease

Symptoms & Phenotypes for Non-Alcoholic Fatty Liver Disease

Drugs & Therapeutics for Non-Alcoholic Fatty Liver Disease

Drugs for Non-Alcoholic Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 498)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Losartan Approved Phase 4 114798-26-4 3961
2
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
3
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
4
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
5
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
6
Insulin glulisine Approved Phase 4 207748-29-6
7
Liraglutide Approved Phase 4 204656-20-2 44147092
8
Glucagon Approved Phase 4 16941-32-5
9
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
10
Insulin Detemir Approved Phase 4 169148-63-4 5311023
11
Insulin Aspart Approved Phase 4 116094-23-6 16132418
12
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
13
Gliclazide Approved Phase 4 21187-98-4 3475
14
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
15
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
16
Propranolol Approved, Investigational Phase 4 525-66-6 4946
17
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
18
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
19
Tamoxifen Approved Phase 4 10540-29-1 2733526
20
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
21
Ergotamine Approved Phase 4 113-15-5 8223
22
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
23
Nortriptyline Approved Phase 4 72-69-5 4543
24
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
25
Zidovudine Approved Phase 4 30516-87-1 35370
26
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
27
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
28
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
29
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
30
Glimepiride Approved Phase 4 93479-97-1 3476
31
Phentermine Approved, Illicit Phase 4 122-09-8 4771
32
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
33
Aminolevulinic acid Approved Phase 4 106-60-5 137
34
tannic acid Approved Phase 4 1401-55-4
35
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
36
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
37
Testosterone enanthate Approved Phase 4 315-37-7 9416
38
Methyltestosterone Approved Phase 4 58-18-4 6010
39
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
40
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
41
Empagliflozin Approved Phase 4 864070-44-0
42
Dulaglutide Approved, Investigational Phase 4 923950-08-7
43
Alogliptin Approved Phase 4 850649-61-5 11450633
44
Metformin Approved Phase 4 657-24-9 4091 14219
45
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
46
Zinc Approved, Investigational Phase 4 7440-66-6 32051
47
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
48
Rifaximin Approved, Investigational Phase 4 80621-81-4 46783403 6436173
49
Insulin glargine Approved Phase 4 160337-95-1
50
Saxagliptin Approved Phase 4 361442-04-8 11243969

Interventional clinical trials:

(show top 50) (show all 1251)
# Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
3 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
4 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
5 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
6 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
7 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
8 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Unknown status NCT02303730 Phase 4 Exenatide;insulin glargine
9 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
10 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
11 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
12 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
13 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
14 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
15 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
16 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
17 Treatment by Subcutaneous Continuous Infusion of Insulin by Portable Pump Versus Discontinuous Infusion of Insulin by Multi-injections in the Type 2 Diabetes: Study of the Insulinosensibility in the 2 Types of Treatments Unknown status NCT01889914 Phase 4 2 different procedures of administration of insulin
18 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
19 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
20 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
21 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
22 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
23 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
24 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
25 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
26 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
27 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
28 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
29 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
30 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
31 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
32 Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus Completed NCT01951651 Phase 4 Exenatide;Glipizide
33 Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
34 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
35 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
36 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
37 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
38 Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus Completed NCT01432405 Phase 4 Exenatide;Pioglitazone
39 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
40 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
41 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
42 Weight Loss Improves Renal Hemodynamics in Patients With Metabolic Syndrome Completed NCT01356394 Phase 4
43 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
44 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
45 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
46 Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
47 Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Completed NCT01155206 Phase 4 glucagon
48 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
49 A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepatotoxicity of ARIMIDEX Compared With Tamoxifen in Adjuvant Therapy in Postmenopausal Women With Hormone Receptor+ Early Breast Cancer Completed NCT00537771 Phase 4 Anastrozole;Tamoxifen
50 Effects of Metformin on Body Weight, Composition and Metabolic Derangements in Obese Children. A Randomized Clinical Trial Completed NCT02274948 Phase 4 Metformin;Placebo

Search NIH Clinical Center for Non-Alcoholic Fatty Liver Disease

Genetic Tests for Non-Alcoholic Fatty Liver Disease

Anatomical Context for Non-Alcoholic Fatty Liver Disease

MalaCards organs/tissues related to Non-Alcoholic Fatty Liver Disease:

41
Liver, Testes, Heart, Endothelial, Ovary, Kidney, Bone

Publications for Non-Alcoholic Fatty Liver Disease

Articles related to Non-Alcoholic Fatty Liver Disease:

(show top 50) (show all 15390)
# Title Authors PMID Year
1
Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. 38 88
20956972 2011
2
Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. 38 88
20497147 2010
3
Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. 38 88
19780876 2010
4
Adipocytes as lipid sensors of oleic acid transport through a functional Caco-2/HT29-MTX intestinal barrier. 38
30905315 2019
5
Long non-coding RNA NEAT1 promotes steatosis via enhancement of estrogen receptor alpha-mediated AQP7 expression in HepG2 cells. 38
31062612 2019
6
PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease. 38
31062641 2019
7
Hepatoprotective effects of Cassia semen ethanol extract on non-alcoholic fatty liver disease in experimental rat. 38
30757944 2019
8
Turnover of bile acids in liver, serum and caecal content by high-fat diet feeding affects hepatic steatosis in rats. 38
31170503 2019
9
Exploring the protective effect of ShengMai-Yin and Ganmaidazao decoction combination against type 2 diabetes mellitus with nonalcoholic fatty liver disease by network pharmacology and validation in KKAy mice. 38
31216433 2019
10
Creatine supplementation exacerbates ethanol-induced hepatic damage in mice. 38
31265967 2019
11
Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. 38
30472683 2019
12
Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. 38
30315891 2019
13
Traditional Chinese Medicine and Intestinal Microbiota: A Complementary and Integrative Health Approach to Ameliorate Obesity-Related Diseases. 38
30648978 2019
14
Gut microbiome and microbial metabolites: a new system affecting metabolic disorders. 38
30788772 2019
15
Application of a layered model for determination of the elasticity of biological systems. 38
31252332 2019
16
Ascorbic acid attenuates cell stress by activating the fibroblast growth factor 21/fibroblast growth factor receptor 2/adiponectin pathway in HepG2 cells. 38
31322211 2019
17
Biomechanics of cultured hepatic cells during different steatogenic hits. 38
31151002 2019
18
Role and effective therapeutic target of gut microbiota in NAFLD/NASH. 38
31410156 2019
19
(5R)-5-hydroxytriptolide ameliorates liver lipid accumulation by suppressing lipid synthesis and promoting lipid oxidation in mice. 38
31301418 2019
20
Inter-platform reproducibility of ultrasonic attenuation and backscatter coefficients in assessing NAFLD. 38
30783789 2019
21
Invited review: Sphingolipid biology in the dairy cow: The emerging role of ceramide. 38
31301829 2019
22
Downregulation of hedgehog ligands in human simple steatosis may protect against nonalcoholic steatohepatitis: Is TAZ a crucial regulator? 38
31087761 2019
23
Gender effect of hyperuricemia on the development of nonalcoholic fatty liver disease (NAFLD): A clinical analysis and mechanistic study. 38
31252266 2019
24
Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease. 38
30888972 2019
25
Spinal miR-34a regulates inflammatory pain by targeting SIRT1 in complete Freund's adjuvant mice. 38
31296380 2019
26
PNPLA3 gene polymorphism in Brazilian patients with type 2 diabetes: A prognostic marker beyond liver disease? 38
31377187 2019
27
Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus? 38
31301336 2019
28
Mouse trefoil factor 3 ameliorated high-fat-diet-induced hepatic steatosis via increasing peroxisome proliferator-activated receptor-α-mediated fatty acid oxidation. 38
31211621 2019
29
Understanding Environmental Contaminants' Direct Effects on Non-alcoholic Fatty Liver Disease Progression. 38
31090041 2019
30
Hypoxia inducible factor-1 promotes liver fibrosis in nonalcoholic fatty liver disease by activating PTEN/p65 signaling pathway. 38
31009107 2019
31
Depression is associated with non-alcoholic fatty liver disease among adults in the United States. 38
31328300 2019
32
Relationship between abdominal fat stores and liver fat, pancreatic fat, and metabolic comorbidities in a pediatric population with non-alcoholic fatty liver disease. 38
31312893 2019
33
New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer. 38
31185249 2019
34
Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. 38
31145929 2019
35
Nicotinamide riboside, an NAD+ precursor, attenuates the development of liver fibrosis in a diet-induced mouse model of liver fibrosis. 38
31195117 2019
36
Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. 38
30888971 2019
37
Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes. 38
30847862 2019
38
Nonalcoholic Fatty Liver Disease and Obesity Treatment. 38
30945129 2019
39
Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives. 38
31175629 2019
40
Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized Obesity. 38
31144261 2019
41
Helicobacter pylori Infection: One More Contributor to Nonalcoholic Fatty Liver Disease Pathophysiology. 38
31033804 2019
42
Mitochondrial dysfunction in high-fat diet-induced nonalcoholic fatty liver disease: The alleviating effect and its mechanism of Polygonatum kingianum. 38
31387169 2019
43
The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression. 38
30778201 2019
44
High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytes. 38
30919112 2019
45
Microbiota and nonalcoholic fatty liver disease: promising prospects for clinical interventions? 38
31219825 2019
46
Curcuminoids plus piperine improve nonalcoholic fatty liver disease: A clinical trial. 38
31168845 2019
47
Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. 38
31353974 2019
48
Psychotropic Medications Are Associated With Increased Liver Disease Severity in Pediatric Nonalcoholic Fatty Liver Disease. 38
31124886 2019
49
Protective effect of genistein on nonalcoholic fatty liver disease (NAFLD). 38
31176163 2019
50
Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation. 38
30732555 2019

Variations for Non-Alcoholic Fatty Liver Disease

ClinVar genetic disease variations for Non-Alcoholic Fatty Liver Disease:

6 (show all 46)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PNPLA3 NM_025225.3(PNPLA3): c.444C> G (p.Ile148Met) single nucleotide variant drug response rs738409 22:44324727-44324727 22:43928847-43928847
2 PNPLA3 NM_025225.3(PNPLA3): c.*141T> G single nucleotide variant Uncertain significance rs886057602 22:44342403-44342403 22:43946523-43946523
3 PNPLA3 NM_025225.3(PNPLA3): c.1419C> T (p.Pro473=) single nucleotide variant Uncertain significance rs376208148 22:44342235-44342235 22:43946355-43946355
4 PNPLA3 NM_025225.3(PNPLA3): c.*990T> A single nucleotide variant Uncertain significance rs886057604 22:44343252-44343252 22:43947372-43947372
5 PNPLA3 NM_025225.3(PNPLA3): c.*1076C> T single nucleotide variant Uncertain significance rs886057605 22:44343338-44343338 22:43947458-43947458
6 PNPLA3 NM_025225.3(PNPLA3): c.*989dup duplication Uncertain significance rs3083314 22:44343251-44343251 22:43947371-43947371
7 PNPLA3 NM_025225.3(PNPLA3): c.*1068C> T single nucleotide variant Uncertain significance rs746640250 22:44343330-44343330 22:43947450-43947450
8 PNPLA3 NM_025225.3(PNPLA3): c.-44C> G single nucleotide variant Uncertain significance rs773713393 22:44319748-44319748 22:43923868-43923868
9 PNPLA3 NM_025225.3(PNPLA3): c.216T> C (p.Leu72=) single nucleotide variant Uncertain significance rs147412464 22:44322843-44322843 22:43926963-43926963
10 PNPLA3 NM_025225.3(PNPLA3): c.646A> C (p.Thr216Pro) single nucleotide variant Uncertain significance rs35726887 22:44328917-44328917 22:43933037-43933037
11 PNPLA3 NM_025225.3(PNPLA3): c.659A> G (p.Tyr220Cys) single nucleotide variant Uncertain significance rs143392071 22:44328930-44328930 22:43933050-43933050
12 PNPLA3 NM_025225.3(PNPLA3): c.980-14A> C single nucleotide variant Uncertain significance rs781212740 22:44335859-44335859 22:43939979-43939979
13 PNPLA3 NM_025225.3(PNPLA3): c.1112+14G> A single nucleotide variant Uncertain significance rs138736228 22:44336019-44336019 22:43940139-43940139
14 PNPLA3 NM_025225.3(PNPLA3): c.*960T> G single nucleotide variant Uncertain significance rs886057603 22:44343222-44343222 22:43947342-43947342
15 PNPLA3 NM_025225.3(PNPLA3): c.*987_*989dup duplication Uncertain significance rs3083314 22:44343249-44343251 22:43947369-43947371
16 PNPLA3 NM_025225.3(PNPLA3): c.*1175A> C single nucleotide variant Uncertain significance rs529050829 22:44343437-44343437 22:43947557-43947557
17 PNPLA3 NM_025225.3(PNPLA3): c.*626A> G single nucleotide variant Uncertain significance rs564752977 22:44342888-44342888 22:43947008-43947008
18 PNPLA3 NM_025225.3(PNPLA3): c.*19T> G single nucleotide variant Uncertain significance rs569255289 22:44342281-44342281 22:43946401-43946401
19 PNPLA3 NM_025225.3(PNPLA3): c.*71T> G single nucleotide variant Uncertain significance rs886057601 22:44342333-44342333 22:43946453-43946453
20 PNPLA3 NM_025225.3(PNPLA3): c.1209C> T (p.Pro403=) single nucleotide variant Uncertain significance rs184910573 22:44340667-44340667 22:43944787-43944787
21 PNPLA3 NM_025225.3(PNPLA3): c.1340G> A (p.Arg447Gln) single nucleotide variant Uncertain significance rs147289545 22:44342156-44342156 22:43946276-43946276
22 PNPLA3 NM_025225.3(PNPLA3): c.414C> T (p.Val138=) single nucleotide variant Uncertain significance rs768191646 22:44323041-44323041 22:43927161-43927161
23 PNPLA3 NM_025225.3(PNPLA3): c.1358G> T (p.Ser453Ile) single nucleotide variant Likely benign rs6006460 22:44342174-44342174 22:43946294-43946294
24 PNPLA3 NM_025225.3(PNPLA3): c.*691_*692dup duplication Likely benign rs397716964 22:44342953-44342954 22:43947073-43947074
25 PNPLA3 NM_025225.3(PNPLA3): c.*889A> G single nucleotide variant Likely benign rs1810508 22:44343151-44343151 22:43947271-43947271
26 PNPLA3 NM_025225.3(PNPLA3): c.*988_*989dup duplication Likely benign rs3083314 22:44343250-44343251 22:43947370-43947371
27 PNPLA3 NM_025225.3(PNPLA3): c.*1090A> G single nucleotide variant Likely benign rs9626058 22:44343352-44343352 22:43947472-43947472
28 PNPLA3 NM_025225.3(PNPLA3): c.343G> T (p.Gly115Cys) single nucleotide variant Likely benign rs2076212 22:44322970-44322970 22:43927090-43927090
29 PNPLA3 NM_025225.3(PNPLA3): c.561C> T (p.Phe187=) single nucleotide variant Likely benign rs34179073 22:44328832-44328832 22:43932952-43932952
30 PNPLA3 NM_025225.3(PNPLA3): c.1359C> G (p.Ser453Arg) single nucleotide variant Likely benign rs76510336 22:44342175-44342175 22:43946295-43946295
31 PNPLA3 NM_025225.3(PNPLA3): c.*429T> C single nucleotide variant Likely benign rs41278873 22:44342691-44342691 22:43946811-43946811
32 PNPLA3 NM_025225.3(PNPLA3): c.295T> G (p.Cys99Gly) single nucleotide variant Likely benign rs2076213 22:44322922-44322922 22:43927042-43927042
33 PNPLA3 NM_025225.3(PNPLA3): c.1300A> G (p.Lys434Glu) single nucleotide variant Likely benign rs2294918 22:44342116-44342116 22:43946236-43946236
34 PNPLA3 NM_025225.3(PNPLA3): c.309G> A (p.Pro103=) single nucleotide variant Likely benign rs79118505 22:44322936-44322936 22:43927056-43927056
35 PNPLA3 NM_025225.2(PNPLA3): c.-168C> A single nucleotide variant Likely benign rs140746182 22:44319624-44319624 22:43923744-43923744
36 PNPLA3 NM_025225.3(PNPLA3): c.187+12G> A single nucleotide variant Likely benign rs116795637 22:44319990-44319990 22:43924110-43924110
37 PNPLA3 NM_025225.3(PNPLA3): c.972C> T (p.Leu324=) single nucleotide variant Likely benign rs116679026 22:44333145-44333145 22:43937265-43937265
38 PNPLA3 NM_025225.3(PNPLA3): c.980-15A> C single nucleotide variant Likely benign rs144872932 22:44335858-44335858 22:43939978-43939978
39 PNPLA3 NM_025225.3(PNPLA3): c.992A> G (p.Glu331Gly) single nucleotide variant Likely benign rs144233415 22:44335885-44335885 22:43940005-43940005
40 PNPLA3 NM_025225.2(PNPLA3): c.-112A> T single nucleotide variant Likely benign rs531789428 22:44319680-44319680 22:43923800-43923800
41 PNPLA3 NM_025225.2(PNPLA3): c.-111G> A single nucleotide variant Likely benign rs548897706 22:44319681-44319681 22:43923801-43923801
42 PNPLA3 NM_025225.3(PNPLA3): c.-40C> G single nucleotide variant Likely benign rs144821153 22:44319752-44319752 22:43923872-43923872
43 PNPLA3 NM_025225.3(PNPLA3): c.*63C> T single nucleotide variant Likely benign rs2294919 22:44342325-44342325 22:43946445-43946445
44 PNPLA3 NM_025225.3(PNPLA3): c.*747T> A single nucleotide variant Likely benign rs62228000 22:44343009-44343009 22:43947129-43947129
45 PNPLA3 NM_025225.3(PNPLA3): c.*707T> C single nucleotide variant Likely benign rs2008451 22:44342969-44342969 22:43947089-43947089
46 PNPLA3 NM_025225.3(PNPLA3): c.447C> T (p.Pro149=) single nucleotide variant Likely benign rs738408 22:44324730-44324730 22:43928850-43928850

Cosmic variations for Non-Alcoholic Fatty Liver Disease:

9 (show top 50) (show all 3417)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1626018 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 54
2 COSM1615665 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 54
3 COSM1602238 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 54
4 COSM6951673 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 54
5 COSM1616325 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 54
6 COSM3707827 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 54
7 COSM3707828 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 54
8 COSM1623051 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 54
9 COSM1612127 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 54
10 COSM1618451 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581L 4:145885684-145885684 54
11 COSM1611545 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 54
12 COSM1612685 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47V 19:52002156-52002156 54
13 COSM1612018 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 54
14 COSM1618219 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 54
15 COSM1624399 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 54
16 COSM1609798 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 54
17 COSM1605856 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 54
18 COSM1602404 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 54
19 COSM1607880 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221A 14:67807621-67807621 54
20 COSM3661787 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 54
21 COSM1270878 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 54
22 COSM1612900 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 54
23 COSM3663890 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 54
24 COSM6969923 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 54
25 COSM3717069 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 54
26 COSM6219678 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 54
27 COSM1613453 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 54
28 COSM3717124 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 54
29 COSM1608898 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 54
30 COSM3705381 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 54
31 COSM1601838 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 54
32 COSM1610770 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 54
33 COSM1601260 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 54
34 COSM1624206 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2136A>G p.T712T 8:80518852-80518852 54
35 COSM1624207 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2311A>G p.I771V 8:80519295-80519295 54
36 COSM1616586 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 54
37 COSM1624117 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1568A>G p.N523S 8:63187582-63187582 54
38 COSM1603361 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 54
39 COSM1617254 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167N 3:183722100-183722100 54
40 COSM3663693 XPO7 liver,NS,carcinoma,hepatocellular carcinoma c.806A>G p.Y269C 8:21977812-21977812 54
41 COSM1609152 XPO6 liver,NS,carcinoma,hepatocellular carcinoma c.882C>T p.G294G 16:28156289-28156289 54
42 COSM6957749 XPO1 liver,NS,carcinoma,hepatocellular carcinoma c.301+1G>C p.? 2:61522610-61522610 54
43 COSM1624082 XKR4 liver,NS,carcinoma,hepatocellular carcinoma c.1076A>G p.D359G 8:55523350-55523350 54
44 COSM1613650 XIRP2 liver,NS,carcinoma,hepatocellular carcinoma c.9350G>C p.R3117P 2:167250742-167250742 54
45 COSM3660541 XIRP1 liver,NS,carcinoma,hepatocellular carcinoma c.142C>A p.Q48K 3:39189304-39189304 54
46 COSM1625463 XIAP liver,NS,carcinoma,hepatocellular carcinoma c.493G>T p.A165S 23:123886155-123886155 54
47 COSM3663909 WWP1 liver,NS,carcinoma,hepatocellular carcinoma c.210-2A>G p.? 8:86381503-86381503 54
48 COSM1625309 WWC3 liver,NS,carcinoma,hepatocellular carcinoma c.1121C>A p.S374Y 23:10117180-10117180 54
49 COSM1621161 WTAP liver,NS,carcinoma,hepatocellular carcinoma c.283C>T p.Q95* 6:159748200-159748200 54
50 COSM6909096 WT1 liver,NS,carcinoma,hepatocellular carcinoma c.1019T>G p.L340* 11:32396283-32396283 54

Expression for Non-Alcoholic Fatty Liver Disease

Search GEO for disease gene expression data for Non-Alcoholic Fatty Liver Disease.

Pathways for Non-Alcoholic Fatty Liver Disease

Pathways related to Non-Alcoholic Fatty Liver Disease according to KEGG:

37
# Name Kegg Source Accession
1 Non-alcoholic fatty liver disease (NAFLD) hsa04932
2 Glycerolipid metabolism hsa00561

Pathways related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.81 MIR34A MIR29C MIR26A1 MIR21 MIR200B MIR200A
2 10.77 MIR200B MIR200A MIR107

GO Terms for Non-Alcoholic Fatty Liver Disease

Cellular components related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 MIR29C MIR26A1 MIR21 MIR151A MIR140 MIR132

Biological processes related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.91 MIR34A MIR21 MIR140 MIR132
2 positive regulation of protein kinase B signaling GO:0051897 9.77 MIR21 MIR132 MIR126
3 positive regulation of angiogenesis GO:0045766 9.76 MIR21 MIR132 MIR130A MIR126
4 negative regulation of cell migration GO:0030336 9.73 MIR34A MIR29C MIR21
5 negative regulation of gene expression GO:0010629 9.73 MSR1 MIR33A MIR29C MIR21 MIR200B MIR132
6 cellular response to hypoxia GO:0071456 9.72 MIR34A MIR140 MIR126
7 negative regulation of angiogenesis GO:0016525 9.71 MIR34A MIR29C MIR21 MIR200B
8 miRNA mediated inhibition of translation GO:0035278 9.7 MIR21 MIR132 MIR107
9 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.67 MIR29C MIR26A1 MIR21
10 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.65 MIR26A1 MIR21 MIR130A
11 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.62 MIR34A MIR140
12 negative regulation of blood vessel endothelial cell migration GO:0043537 9.61 MIR200B MIR132
13 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.61 MIR132 MIR126 MIR10B
14 triglyceride homeostasis GO:0070328 9.59 MIR34A MIR33A
15 positive regulation of cell cycle arrest GO:0071158 9.58 MIR34A MIR200B
16 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.58 MIR29C MIR26A1
17 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.57 MIR26A1 MIR21
18 negative regulation of cholesterol efflux GO:0090370 9.54 MIR33A MIR26A1
19 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.54 MIR132 MIR126 MIR10B
20 gene silencing by miRNA GO:0035195 9.53 MIR34A MIR33A MIR29C MIR26A1 MIR21 MIR200B
21 negative regulation of cell cycle G1/S phase transition GO:1902807 9.51 MIR29C MIR26A1
22 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.5 MIR34A MIR21 MIR140
23 negative regulation of vascular endothelial cell proliferation GO:1905563 9.46 MIR34A MIR29C MIR132 MIR126
24 positive regulation of vascular endothelial cell proliferation GO:1905564 9.26 MIR21 MIR132 MIR130A MIR126

Molecular functions related to Non-Alcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.44 MIR34A MIR33A MIR29C MIR26A1 MIR21 MIR200B
2 RNA polymerase II complex binding GO:0000993 9.13 MIR33A MIR140 MIR126

Sources for Non-Alcoholic Fatty Liver Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....